Last reviewed · How we verify
Carboplatin-Nab-Paclitaxel
Carboplatin-Nab-Paclitaxel is a Small molecule drug developed by Tesaro, Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | Carboplatin-Nab-Paclitaxel |
|---|---|
| Sponsor | Tesaro, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (PHASE3)
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
- A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors (PHASE1)
- Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial (PHASE3)
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carboplatin-Nab-Paclitaxel CI brief — competitive landscape report
- Carboplatin-Nab-Paclitaxel updates RSS · CI watch RSS
- Tesaro, Inc. portfolio CI
Frequently asked questions about Carboplatin-Nab-Paclitaxel
What is Carboplatin-Nab-Paclitaxel?
Carboplatin-Nab-Paclitaxel is a Small molecule drug developed by Tesaro, Inc..
Who makes Carboplatin-Nab-Paclitaxel?
Carboplatin-Nab-Paclitaxel is developed by Tesaro, Inc. (see full Tesaro, Inc. pipeline at /company/tesaro-inc).
What development phase is Carboplatin-Nab-Paclitaxel in?
Carboplatin-Nab-Paclitaxel is in Phase 1.
Related
- Manufacturer: Tesaro, Inc. — full pipeline
- Compare: Carboplatin-Nab-Paclitaxel vs similar drugs
- Pricing: Carboplatin-Nab-Paclitaxel cost, discount & access